Global Blood Therapeutics Profit Margin 2014-2021 | GBT
Current and historical gross margin, operating margin and net profit margin for Global Blood Therapeutics (GBT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Global Blood Therapeutics net profit margin as of June 30, 2021 is -161.55%.
|Global Blood Therapeutics Annual Profit Margins
|Global Blood Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.